10-Q quarterly report · filed Oct 29, 2026

BridgeBio Pharma, Inc. (BBIO) Q3 2026 10-Q Quarterly Report

Short answer

BridgeBio Pharma, Inc. (BBIO) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $353M (up 192.6% year over year) with net income of −$57M.

Q3 2026 key financials · XBRL

Revenue
$353M
+192.6% YoY · +44.9% QoQ
Net income
−$57M
+69.0% YoY · +62.7% QoQ
Operating margin
-3.3%
EPS (diluted)
−$0.42
+55.8% YoY · +46.2% QoQ

Source: XBRL data from the BridgeBio Pharma, Inc. (BBIO) Q3 2026 10-Q on SEC EDGAR. USD.

BridgeBio Pharma, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $353.2M, up $232.5M YoY, driven by Attruby product revenue $253.3M vs $108.1M
  • Operating margin negative 3.3% vs negative 120.3% YoY, based on operating loss $11.6M vs $145.2M
  • Best line: Attruby revenue up $145.3M; worst line: license and services revenue up $71.0M, boosted by a $75.0M Bayer milestone
  • Cash, equivalents and securities $1.5B vs $587.5M; operating cash outflow $312.6M for nine months
  • Near-term losses expected for several years; liquidity projected for at least 12 months, with headwinds from commercialization, inflation and supply chain issues

Risk Factors

  • New regulatory risk: CMS finalized GLOBE on October 2, 2026, requiring internationally benchmarked Medicare Part B rebates beginning January 1, 2027
  • Most material update: FDA scrutiny of promotional practices, including an untitled letter concerning Attruby’s DTC broadcast advertisement
  • Compliance exposure: Medicaid, 340B and VA pricing errors could trigger refunds, civil penalties, or program termination
  • Commercial risk: Attruby faces competition as it is not the first ATTR-CM treatment on the market
  • Supply risk: Attruby and Beyonttra rely on one primary drug-product supplier, despite a secondary supplier agreement

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other BridgeBio Pharma, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.